Skip to content

    Akums Drugs

    India's largest CDMO by revenue, capacity and clients, also making branded formulations and APIs.

    Healthcare
    Healthcare
    View AKUMS earnings calls
    ₹604.7
    +11.30% from avg

    Overview

    Price

    ₹604.7

    Market Cap

    ₹10.4k Cr

    Sector

    Healthcare

    Healthcare

    Rank

    3

    Performance

    Financials

    Income Statement

    Financial Trajectories

    11
    Quarterly

    Balance Sheet

    Balance Sheet

    ₹ Cr · Annual
    Line itemFY20FY21FY22FY23FY24FY25FY26FY26
    LiabilitiesEquity Capital11142929313131
    Reserves7218846086896813.0k3.1k3.3k
    Borrowings1751303956195658890157
    Other Liabilities1.1k1.1k2.0k1.9k2.2k9601.9k2.0k
    Total Liabilities2.0k2.2k3.0k3.2k3.5k4.1k5.2k5.4k
    AssetsFixed Assets6459041.0k1.1k1.2k1.4k1.4k1.5k
    CWIP571731103195163158177
    Investments620000000
    Other Assets1.3k1.2k2.0k2.0k2.1k2.5k3.6k3.8k
    Total Assets2.0k2.2k3.0k3.2k3.5k4.1k5.2k5.4k

    Cash Flow

    Cash Flow

    ₹ Cr · Annual
    Line itemFY16FY20FY21FY22FY23FY24FY25FY26
    ActivitiesCash from Operating8928131321774984651.2k
    Cash from Investing-123-190-109-235-305-331-548-930
    Cash from Financing37233-91236125-1087334
    SummaryCapital Expenditure
    Free Cash Flow-34-3449-224-110212201958
    FCF Margin

    Valuation

    Cyclical, with too little history

    This looks cyclical, and we don't have enough quarters to establish a through-cycle earnings base. Valuing it off the current point in the cycle would be misleading.

    AKUMS · CYCLICAL_UNMODELABLE

    Learn to analyse Akums Drugs

    Guides on how to read this kind of business and the numbers that matter.